ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
announced its financial results for the quarter ended March 31,
2017. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
99.1) shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
|
(d)
|
Exhibits
|
furnished, and not filed:
|
99.1
|
Press release issued by the Company on May 4, 2017
|
||
About ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO)
Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF). ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) Recent Trading Information
ELEVEN BIOTHERAPEUTICS, INC. (NASDAQ:EBIO) closed its last trading session 00.00 at 1.85 with 209,096 shares trading hands.
